

## CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R. SECTION 1.8

I hereby certify that this correspondence is being deposited, pursuant to 37 C.F.R. Section 1.8, with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on this  $\sqrt{\frac{1}{2}}$  of  $\sqrt{\frac{1}{2}}$   $\sqrt{\frac{1$ 

Richard R. Muccino

Reg. No. 32,538

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent Application:

Brandt et al.

Group Art Unit:

Serial No: 10/081,309, filed February 21, 2002

Examiner:

For: PEG CONJUGATES OF NK4

Supplementary Response Pursuant To 37 C.F.R. Section 1.115

Nutley, New Jersey 07110 May 15 2002

Commissioner for Patents Washington, D.C. 20231

This Supplementary Response pursuant to 37 C.F.R. Section 1.115 is in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Sequence Disclosures dated 22 March 2002 in the above-identified patent application.

Applicant requests that the Examiner consider the following response and pass the above-identified application to issue.

Brandt et al.

Serial No: 10/081,309

Filed February 21, 2002

Page 2

## **RESPONSE**

As set out above, applicant has submitted this Supplementary Response in reply to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Sequence Disclosures in the above-identified patent application.

In response to this Notice, applicant has submitted herewith a Sequence Listing of the nucleotide and/or amino acid sequences in the aboveapplication identified patent on paper copy in accord with 37 C.F.R. Section 1.821(c) and in computer readable form in accord with 37 C.F.R. Section 1.821(e). Applicant has also filed herewith a statement pursuant to 37 C.F.R. Section 1.821(f) that the content of the paper copy and computer readable copy are the same and a statement pursuant to 37 C.F.R. Section 1.821(g) that the submission of the paper copy and the computer readable copy includes no new matter.

In accord with 37 C.F.R. Sections 1.821(c) and 1.821(d), applicant has provided this response to include references to each sequence disclosed in the Sequence Listing by use of the separate identifiers written as SEQ ID NO:1, SEQ ID NO:2, etc. Applicant has already provided references in the application as filed to each sequence disclosed in the Sequence Listing by use of the separate identifiers, written as SEQ ID NO:1, SEQ ID NO:2, etc..

In view of the foregoing response, applicant requests allowance of the claims pending in this application. Applicant requests the Examiner to Brandt et al.

Serial No: 10/081,309 Filed February 21, 2002

Page 3

telephone the undersigned attorney should the Examiner have any questions or comments which might be most expeditiously handled by a telephone conference.

Applicant's attorney authorizes the Examiner to charge Deposit Account 12-2525 if there are any additional charges in connection with this response and amendment.

Respectfully submitted,

Brandt et al.

By Kidrend ICH Wellin

Richard R. Muccino Reg. No. 32,538

Attorney for Applicant(s)

Direct communications to: George W. Johnston, Esq. Hoffmann-La Roche Inc. 340 Kingsland Street

Nutley, New Jersey 07110-1199 Telephone: (973) 235-3656

Telefax: (973) 235-2363